Henry Ford Health

Henry Ford Health Scholarly Commons
Orthopedics Articles

Orthopedics / Bone and Joint Center

9-27-2022

Soluble Biomarkers in Osteoarthritis in 2022: Year in review
Francisco Rocha
Shabana A. Ali

Follow this and additional works at: https://scholarlycommons.henryford.com/orthopaedics_articles

Osteoarthritis and Cartilage xxx (xxxx) xxx

Review

Soluble biomarkers in osteoarthritis in 2022: year in review
F.A.C. Rocha y *, S.A. Ali z x k
, Fortaleza, CE 60430-270, Brazil
y Department of Internal Medicine, Faculdade de Medicina, Universidade Federal do Ceara
z Bone and Joint Center, Department of Orthopaedic Surgery, Henry Ford Health System, Detroit, MI, USA
x Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA
k Department of Physiology, Michigan State University, East Lansing, MI, USA

a r t i c l e i n f o

s u m m a r y

Article history:
Received 27 July 2022
Accepted 20 September 2022

Objective: To review articles reporting on the development of soluble biomarkers in osteoarthritis (OA)
over the past year.
Design: Two literature searches were conducted using the PubMed database for articles published between April 1, 2021 and March 31, 2022. Two searches were done, one on soluble biomarkers and
another on circulating non-coding RNAs in OA. Additional articles were hand-picked to highlight
emerging biomarker trends in OA.
Results: Of 348 publications retrieved, we included 20 articles with 3 that were hand-picked for the
narrative synthesis. We review recent data on soluble biomarkers and circulating non-coding microRNAs
in OA using the BIPED classiﬁcation system. We highlight studies using proteomics to show that cartilage
acidic protein 1 (CRTAC1) is a promising biomarker, helping diagnose and estimate severity in hand, hip,
and knee OA. Subtle changes in the structure of glycosaminoglycans from the extracellular cartilage
matrix were shown to discriminate OA from non-OA cartilage. C-reactive protein metabolite (CRPM) and
collagen metabolites may help discriminate subsets of OA patients as well as disease progression.
Additionally, physical activity may impact determination of biomarkers. We also report on circulating
microRNAs, lncRNAs, and circRNAs in OA and their predictive accuracy in diagnosis and prognosis.
Conclusions: Biomarkers for routine use are still an unmet need in the OA clinical scenario. Emerging
data and novel classes of biomarkers (i.e., non-coding RNAs) show promise. Although still requiring
validation in multiple independent cohorts, the past year brought advances towards a ready-to-use,
reproducible, cost-effective biomarker, namely CRTAC1, to better manage the OA patient.
© 2022 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
The burden of osteoarthritis (OA) cannot be overemphasized as it
is the most common chronic inﬂammatory arthropathy and incurs
substantial social and economic impacts. Although diagnosing
established OA typically does not represent a major challenge even
in primary care settings1, there is still a need to adequately measure
disease severity, prognosis, and response to treatment. An effort to
unify reporting data on biomarkers led to the “BIPED” classiﬁcation,
which stands for Burden of Disease, Investigative, Prognostic, Efﬁcacy of Intervention and Diagnostic, and represents ﬁve classes of
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biomarkers for OA2. Distinguishing OA patients according to clinical
phenotypes that may be associated with molecular characteristics,
which can be clustered as endotypes, may help discriminate patient
groups and possibly inﬂuence treatment outcome and prognosis2e4.
In this year in review article, our aim is to provide a narrative
review summarizing publications presenting data that may point to
novel trends in the OA biomarker ﬁeld. This includes work showing
that plasma levels of the cartilage acidic protein 1 (CRTAC1) are
positively associated not only with an OA diagnosis but also with
disease severity5. We also review qualitative alterations of the
charge of extracellular matrix components, speciﬁcally glycosaminoglycans, that may help design biomarkers in OA6e8.
Additionally, we review recent evidence for a potential novel class
of biomarkers for OA, namely non-coding RNAs. Among non-coding
RNAs, microRNAs, long non-coding RNAs (lncRNAs), and circular
RNAs (circRNAs) have been most explored in the context of OA and
represent promising biomarkers for minimally-invasive, affordable,
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and reliable identiﬁcation of disease9. Though circulating microRNAs
were ﬁrst explored as potential biomarkers for OA in 201010 (Fig. 1),
advances in proﬁling technologies including microRNA-sequencing11
have prompted a surge in studies seeking to elucidate microRNAs as
diagnostic and prognostic biomarkers for OA.
Methods
We conducted two literature searches in the PubMed electronic
database for publications describing human studies on biomarkers in
the period between April 1, 2021 and March 31, 2022, considering
epub articles if the date of availability was within this period of time,
as follows: 1. Soluble biomarkers: ((((osteoarthritis) OR (arthrosis))
OR (osteoarthrosis))) AND (biomarker [Title/Abstract] OR serum
[Title/Abstract] OR plasma [Title/Abstract] OR urine [Title/Abstract]
OR synovial ﬂuid [Title/Abstract]). Filters included Clinical Study,
Clinical Trial, Controlled Clinical Trial, English Abstract, Randomized
Controlled Trial, Humans, English language; and 2. Non-coding
RNAs: (("osteoarthritis"[MeSH Terms] OR "osteoarthritis"[All Fields]
OR "osteoarthritides"[All Fields]) AND ("micrornas"[MeSH Terms]
OR ("microrna"[All Fields] AND "mirna"[All Fields]) OR "noncoding
RNA"[All Fields] OR "mir"[All Fields])) AND ((humans[Filter]) AND
(2021/4/1:2022/3/31[pdat])). Results were ﬁrst screened by title and
abstract, then by full-text, applying inclusion and exclusion criteria in
a stepwise approach. Hand-picked articles and an abstract presented
in the European Alliance of Associations for Rheumatology (EULAR)
2021 meeting were also included. Results are presented using the
National Institutes of Health (NIH) proposed classiﬁcation system
“BIPED” as reported previously2,12.
Results
Literature search results
Our ﬁrst search strategy returned 228 articles [Fig. 2(A)]. Titles and
abstracts were screened for the following key terms ¼ ‘osteoarthritis’,

Fig. 1

‘arthrosis’, ‘osteoarthrosis’, 'biomarker', 'serum', 'plasma', 'blood',
‘urine’, and 'synovial ﬂuid'. We excluded any articles that did not use
human samples (N ¼ 3), were not related to OA (N ¼ 174) and were not
related to soluble biomarkers (N ¼ 36). This retained 11 articles. All but
two studies presented data on knee OA with two articles with data on
hip OA, one with hand OA, and another with multiple joints (Table I).
We also included N ¼ 3 hand-picked articles and/or abstracts presented at the EULAR 2021 meeting with data on soluble biomarkers in
OA.
Our second search strategy focused on non-coding RNAs and
returned 124 articles [Fig. 2(B)]. As inclusion criteria, titles and
abstracts were screened for the following key terms ¼ 'biomarker',
'marker', 'serum', 'plasma', 'blood', 'circulating', and 'peripheral'.
This retained 23 articles. We excluded any articles that were not in
English, did not use human samples, were not related to OA, and
were not primary research. We also excluded any articles that reported on tissue expression of microRNAs rather than circulating
levels of microRNAs. This removed 14 articles, leaving a total of 9
articles which we summarize in a narrative review format (Table II).
Burden of disease biomarkers
A major challenge facing development of appropriate burden of
disease biomarkers (i.e., measuring severity of OA) is the lack of
sufﬁciently large studies. This year, a large study comprising 39,155
individuals in Iceland gathered both clinical data and plasma
samples and applied a proteomic approach using a SOMAmer
platform examining 4,792 proteins (SomaLogic; https://somalogic.
com/). SOMAmer stands for Slow off-rate modiﬁed aptamers, which
are single-stranded oligonucleotides that can speciﬁcally bind to
proteins. This was an exploratory study with no ‘hypothesis-driven’
strategy, aiming to identify protein biomarkers that could correctly
identify hand, hip, or knee OA diagnosis. Disease severity for hip
and knee joints was evaluated as a history of joint replacement
obtained in electronic data banks. For hand OA, disease severity
was evaluated using radiographies that were available for scoring5.
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Timeline depicting the increase in studies performing unbiased proﬁling of circulating microRNAs (miRs) in OA over the past decade.
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Flowcharts summarizing the literature search results for A) soluble biomarkers and B) non-coding RNAs in OA.
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Joint

Study population

Biomarker(s)

BIPED entry

Results

Conclusion

Reference

Proteomics;
plasma levels

Knee, Hip, Hand

CRTAC1

Diagnosis/Burden

Styrkarsdottir et al.5
Szilagyi et al.14

Knee

Pro-C2 plasma/serum

Burden

CRTAC1 strongly associated with
Knee > Hip > Hand OA diagnosis;
CRTAC1 associated with knee/hip
OA arthroplasty risk and x-Ray
hand OA severity
Low pro-C2 associated with
increased xRay progression

CRTAC1 levels:
promising biomarker of
knee/hip OA progression
to arthroplasty

Plasma/serum levels
vs xRay progression

- 39,155 individuals; 3
Iceland cohorts;
- 3517 individuals from
Rotterdam prospective
cohort
253 patients (NYU group/sCT
trial SMC021-2301)

Luo et al.15

Serum levels

Knee

519 patients; MOST cohort

Free fatty acids (FFA)

Burden

Serum levels

Knee

620 patients; MOST cohort

Total cholesterol, LDL, HDL

Burden

FFA not associated with OA
development
No association

Serum levels

Knee

30 primary (pOA) vs 16
secondary OA (sOA)

Tumor necrosis factor (TNF)-a,
Interleukin (IL)-1b, IL-6

Diagnosis

No association

Chondroitin
sulfate (CS) structure
(chromatography,
electron microscopy)
Serum levels

Shoulder, Hip

20 shoulder, 10 hip

Molar mass (MM), sulphur (S)
content

Diagnosis

CS from OA cartilage has >MM
and <S

Low pro-C2 serum level
may be more prone to
progression
FFA not suitable as
progression marker
Total cholesterol, LDL,
HDL not suitable as
burden marker
Serum TNF, IL-1, IL-6 do
not distinguish pOA vs
sOA
Structural CS changes
distinguish OA from
non-OA cartilage

Knee; multiple
joints

25 patients

Diagnosis

Increased CRPM associated with
inﬂammatory markers and MMPgenerated metabolites

CRPM may reﬂect
inﬂammation

Alexander et al.19

Serum levels

Knee

781 patients

C-reactive protein (CRP), CRP
metabolite (CRPM), type
I/type III collagen MMPgenerated metabolites
CRP, CRPM

Prognosis

Higher CRPM levels associated
with incident OA

Bay-Jensen et al.26

Serum levels

Knee

447 patients

Prognosis

C3M and CRPM negatively
associated with symptoms

Serum

Knee

200 patients; OAI cohort

Prognosis

ITIH1, C3, S100A6 associated
with xRay progression

Urine

Knee

200 patients received either
intra-articular hyaluronan or
loxoprofen

Intervention

uCTX-II increased following
hyaluronan injection

Hyaluronan may work
differently from
loxoprofen

Ishijima et al.32

Serum; synovial ﬂuid

Knee

225 patients (FORWARD
sprifermin study)

type III collagen degradation
(C3M), CRPM, cartilage
oligomeric protein (COMP)
inter-alpha trypsin inhibitor
heavy chain
1 (ITIH1), complement C3 (C3),
and calcyclin (S100A6)
cross-linked C-terminal type II
collagen telopeptide (CTX-II;
uCTX-II); baseline/after 5 weeks
intervention
Pro-C2

Higher CRPM levels may
distinguish a subset of
knee OA
High CRPM/C3M
associated with worse
OA pain/function
High ITIH1 increases
chance of incident knee
OA

Intervention

Patients with lower proC2 may beneﬁt more
from sprifermin

Bay-Jensen et al.33

Serum

Knee

64 patients (hydrotherapy/
peloidotherapy vs placebo)

Intervention

Serum; urine

Knee

20 patients

IL-1b, insulin-like growth
factor-1 (IGF-1); baseline,
3 and 6 months post intervention
type II collagen degradation,
C2M, fragment of type VI
collagen degradation, C6M, c
COMP, PRO-C2, uCTX-II; baseline
and post intervention

Sprifermin increased synovial
pro-C2; lower baseline pro-C2
associated with increase in
cartilage thickness
No difference in IL-1b or IGF-1

C2M and C6M had trends to
increase or decrease after cycling,
respectively

Exercise may impact
measure of biomarkers

Table I
Summary of articles focusing soluble biomarkers in osteoarthritis in 2021

Intervention

Felson et al.16
Schwager et al.17

Rankothgedera
et al.18
Nunes et al.6,7

Yang et al.27

Lourido et al.28

Adıgüzel et al.34

Bjerre-Bastos
et al.35,36

Osteoarthritis and Cartilage

F.A.C. Rocha, S.A. Ali / Osteoarthritis and Cartilage xxx (xxxx) xxx

Elsevier on October 13, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Please cite this article as: Rocha FAC, Ali SA, Soluble biomarkers in osteoarthritis in 2022: year in review, Osteoarthritis and Cartilage, https://
doi.org/10.1016/j.joca.2022.09.005
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by

Approach

Joint

Study population

Biomarker(s)

BIPED entry

Results

Conclusion

Reference

Serum levels
of miRNAs

Hip

miR-497

Diagnosis

miR-497 is an excellent discriminator
between OA and control with AUC ¼ 0.89
(P < 0.000)

Circulating miR-497 represents a putative
biomarker for hip OA

Pertusa et al.20

Serum levels
of miRNAs

Knee

25 osteoporotic
fracture; 23
osteoarthritis; 52
control
3 OA; 3 control

miR-584-5p, miR183-5p, miR-4435

Diagnosis

Due to the limited sample size
independent validation of these results is
required

Jiang et al.21

PBMC levels
of miRNA

Hip

30 OA; 26 control

miR-206

Diagnosis

Knee

81 OA; 49 control

FER1L4

Diagnosis

Not speciﬁed

60 OA; 60 control

Diagnosis

Knee

10 OA; 10 control

circ_0005526
(circ_RUNX2)
circ_0001103

Plasma levels
of miRNAs

Knee, Hip

22 OA RAAK study;
71 OA GARP study

Prognosis

These 7 miRs have AUC values of 0.86
over 2 years and 0.76 over 5 years in
distinguishing progressors from nonprogressors

Plasma levels
of miRNAs

Knee

Prognosis

miR-320 family members are good
predictors of fast-progressors with AUC
ranging from 82.6 to 91.9

Circulating miR-320 family members
merit further investigation as potential
biomarkers of fast-progressing knee OA

Ali et al.9

Serum levels
of lncRNAs

Knee

20 fast-progressors;
35 slowprogressors; 51 nonprogressors
20 OA

miR-1307-5p, miR140-3p, miR-181a3p, miR-221-5p,
miR-4326, miR4443, miR-99a-5p
miR-320b, miR320c, miR-320d,
miR-320e

AUC analyses are required to determine
the value of circulating miR-206 as a
biomarker for hip OA
FER1L4 efﬁciently identiﬁes OA cases
from control subjects
Circulating circ_RUNX2 may be used as
potential clinical indicator of OA
Due to the limited sample size
independent validation of these results is
required
The signature of 7 plasma miRNAs can
inform future studies on early biomarkers
for prognosticating OA over 2 and 5 years

Ye et al.22

Plasma levels
of lncRNA
Serum levels
of circRNAs
Serum levels
of circRNA

miR-584-5p-KRAS, miR-183-5p-NRAS,
miR-4435-PIK3R3, and miR-4435-SOS1
are four putative regulatory pathways in
OA
Increased miR-206 was positively
correlated with peripheral Th17/Treg
imbalance in hip OA
AUC of 0.92 indicates there may be good
diagnostic value of FER1L4 in OA
AUC of 0.82 indicates there may be good
diagnostic value of circ_RUNX2 in OA
Circulating circ_0001103 is reduced in OA
compared to controls

MZF1-AS1, MALAT1,
LOC100287846

Prognosis

TKR patients with chronic postoperative
pain show preoperative downregulation
of these 3 circulating lncRNAs

Due to the limited sample size
independent validation of these results is
required

Giordano et al.31

Diagnosis

Table II

He et al.23
Wang et al.24
Zhang et al.25

Ramos et al.29
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Data were cross-referenced against classical OA risk factors
including age, sex, and body mass index (BMI). Genetic factors were
considered using data from an OA genome-wide association study
(GWAS) in the UK databank calculating risk scores for individuals in
Iceland that have been genotyped5.
After adjustment for the traditional risk factors associated with
OA and exclusion of other inﬂammatory arthropathies, serum
levels of CRTAC1 displayed the strongest association with a diagnosis of knee OA [odds ratio (OR) 1.46; 95% conﬁdence interval (CI)
1.41e1.52] and was also associated with hip OA [OR 1.36; 95% CI
1.29e1.43] and hand OA [OR 1.33; 95% CI 1.26e1.40]5. Following
CRTAC1, cartilage oligomeric matrix protein (COMP) was the only
protein with plasma levels associated with an OA diagnosis, though
several orders of magnitude below CRTAC1. Although plasma levels
of COMP had a mild correlation with CRTAC1 levels, when adjustment for OA diagnosis was made for CRTAC1 levels, COMP levels
were no longer signiﬁcant whereas CRTAC1 remained signiﬁcant
even when conditioning for plasma levels of COMP. Further,
CRTAC1 levels remained signiﬁcantly associated with an OA diagnosis after adjustment for comorbidities including cancer, cardiovascular, and metabolic diseases. In addition to the strong
association with an OA diagnosis, plasma levels of CRTAC1 were
also positively and signiﬁcantly associated with pain and radiological severity in hand OA patients, as well as with the increase in
the number of joints affected by OA. Concerning hip and knee OA,
joint replacement was taken as a measure of disease severity.
Analysis of all proteins indicated that CRTAC1 levels were the most
signiﬁcantly associated with joint replacement; further, stratiﬁcation of plasma CRTAC1 levels into quintiles showed that those in
the highest quintiles had 16 times higher risk of being subjected to
knee replacement in a period of 5 years.
Despite the robust associations found, CRTAC1 levels were not
considered to be associated with OA pathogenesis and the GWAS
analysis rendered no association of variants of CRTAC1 genes with
OA5. CRTAC1 is a glycoprotein found in the cartilage extracellular
matrix as well as in the joint ﬂuid of OA patients that is reportedly
not linked to OA pathogenesis5. As of today, it has not been isolated
in other tissues, though an alternative splicing isoform, CRTAC1b,
has been isolated in the eye and brain tissues13. Study limitations
include a lack of information on time of sampling and disease onset,
and a heavy reliance on registry data, yet these do not overshadow
its robustness. Although the ﬁndings must be replicated in other
scenarios, another group of researchers used a similar proteomic
approach and reported a strong association of increased plasma
levels of CRTAC1 with both the diagnosis and burden of OA in a
Dutch cohort14. These data point to CRTAC1 as a promising candidate for a reproducible and affordable burden of disease biomarker
to be used in the management of OA patients.
Turning to another large-scale burden of disease study conducted
in the past year, 106 individuals with OA from New York University
(NYU group) and 147 patients from a phase III study on oral salmon
calcitonin (sCT trial SMC021-2301) were examined for OA progression15. The study tested the association between PRO-C2 plasma and
serum levels in the NYU and sCT cohorts, respectively, taken as a
marker of type II collagen formation, and OA severity, assessed
radiologically based on medial joint space narrowing (JSN) over 24
months, while adjusting for age, sex, BMI, race, baseline pain levels
and joint space width. Patients of the NYU group with lower PRO-C2
levels had an increase in JSN progression, while PRO-C2 levels in the
sCT trial group were not signiﬁcantly associated with JSN progression.
When combining the 253 patients, low PRO-C2 levels were associated
with worsening of JSN and those in the lowest quartiles had increased
chance of radiographic progression. Interestingly, patients treated
with sCT who had very low to low PRO-C2 levels at baseline showed a
decrease in JSN progression as compared to those with higher levels of

PRO-C2 (Chi squared ¼ 6.5, P ¼ 0.011). This study presents a possible
distinct OA phenotype, wherein individuals have a low level of
cartilage formation. Apart from the need to reproduce these ﬁndings
in larger and independent cohorts, determination of precise PRO-C2
cut-off values requires validation. Among study limitations, JSN progression appears to be far from an ideal parameter to evaluate
structural damage in OA15.
Two more large-scale studies focusing on burden of disease and
diagnostic biomarkers for OA were reported using the Multicenter
Osteoarthritis study (MOST) cohort. The ﬁrst study explored serum
levels of free fatty acids (FA) in relation to the risk of developing OA.
Among 260 and 259 cases of incident symptomatic and radiographic OA, respectively, after adjusting for classical OA risk factors,
the authors found no association16. The second study with the
MOST cohort included 337 and 283 cases with incident and
radiographic OA, respectively. Again, total cholesterol, LDL, or HDL
levels were not found to be associated with parameters of OA
severity17. Although metabolic comorbidities are very common in
OA patients, these data argue against the use of those lipid levels to
monitor OA severity clinically.
Diagnostic biomarkers
Diagnostic biomarkers seek to identify diseased from
non-diseased individuals. In a recent caseecontrol study aimed at
discriminating primary knee OA (pKOA; N ¼ 30) from secondary
knee OA (sKOA; N ¼ 16) compared to controls and lupus patients,
serum levels of the cytokines tumor necrosis factor (TNF)-a,
Interleukin (IL)-1b, and IL-6 were evaluated18. Study limitations
include a low number of patients per group, probable heterogeneity among patients considered to have sKOA, and difﬁculty
distinguishing pKOA from sKOA; resultingly, there was no association with disease parameters. Furthermore, the cytokines that
were evaluated are relevant in the pathogenesis of various arthropathies and are also present in comorbidities that are prevalent in OA patients, thereby limiting speciﬁcity.
Two studies by Nunes et al. reported structural characteristics
that distinguish glycosaminoglycans (GAG), namely chondroitin
sulfate (CS), extracted from both animals subjected to experimental
OA and humans that had undergone arthroplasty secondary to OA
or fracture, used as controls. In addition to an increase in the CS
content (mg/mg dried cartilage) and in the molar mass of CS in OA
cartilage, there was also a signiﬁcant decrease in the sulphur content in the CS of the OA cartilage, as compared to the non-OA group.
That decrease in sulphur was associated with a signiﬁcant reduction of the negative charge of CS in OA human samples6,7. The
extent to which these changes (i.e., qualitative alterations of GAG
molecules) can be used for diagnosing and/or evaluating the
burden of OA remains to be determined.
Interestingly, another study using a GAG chemical exchange
saturation transfer [gag(CEST)] protocol derived using 3T magnetic
resonance imaging (MRI) was able to discriminate knee OA and
control joints, using direct video-arthroscopy images as a goldstandard comparator. The gagCEST technique takes advantage of
changes in the saturation transfer of protons bound to solutes8.
Given that GAG are highly negatively charged and there is cartilage
loss at least in late stages of OA, a decrease in cartilage GAG content
could be quantitated using the gagCEST technique, thus allowing a
reproducible, observer-independent parameter to assess cartilage
loss. Coupled to the above data showing that GAG from OA cartilage
display decreased sulfation that is associated with a reduced
negative GAG charge7, it might well be possible to determine
whether this occurs in early stages of the disease, thus enabling a
quantitative method to serve as a biomarker of OA diagnosis and/or
burden.
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Another study examined the association of serum levels of Creactive protein (CRP), CRP metabolite (CRPM), and type I/type III
collagen metabolites with radiographic and radionuclide data, using etarfolatide as tracer, in 25 individuals with symptomatic OA19.
Although the authors investigated the association of CRPM with
both isolated and multi-joint inﬂammation in OA patients, challenges included the low number of patients, adjustment for potential confounders, and deﬁnition of site inﬂammation.
Non-coding RNAs
Within our search timeframe, a total of 6 studies measured
circulating non-coding RNAs that could be used to distinguish OA
from control individuals. Of these, 3 focused on microRNAs, 1 on
lncRNAs, and 2 on circRNAs. In the microRNA studies, miR-4975p20, as well as miR-584-5p, miR-183-5p, and miR-4435 were
identiﬁed in serum21, while miR-206 was identiﬁed in peripheral
blood mononuclear cells22. A notable challenge is the lack of
reproducibility in microRNAs across studies, which could be
explained by the different specimens proﬁled, differences in
phenotype deﬁnition, or by the low sample sizes with only N ¼ 3
per group in one study21. Nevertheless, with an area under the
curve (AUC) value of 0.89 for miR-497-5p, microRNAs demonstrate
utility in discerning OA vs controls20.
Though other classes of non-coding RNAs have been far less
explored as biomarkers for OA, a recent study proﬁled the lncRNA
Fer-1-like protein 4 (FER1L4) in plasma. Showing decreased
expression in those with OA (N ¼ 81) compared to controls
(N ¼ 49), predictive models including FER1L4 had an AUC value of
0.92, indicating high accuracy as a diagnostic biomarker23. Two
other studies measured circRNAs in serum, namely circ_0005526
(circ_RUNX2)24 and circ_000110325. While circ_0005526 produced
an AUC value of 0.82, the predictive ability of circ_0001103 was not
reported, likely due to the low sample size (N ¼ 10 per group).
CircRNAs can function as ‘sponges’ to bind microRNAs, with
circ_0005526 reported to bind miR-498, miR-924, miR-361-3p, and
miR-665, each of which regulate gene targets involved in extracellular matrixereceptor interaction pathways24, and circ_0001103
reported to bind miR-375, which regulates Sirtuin 1 (SIRT1), a
regulator of multiple biological processes including inﬂammation25. Regulation of target genes in tissues such as cartilage suggests a connection between these circulating markers and disease
pathophysiology, thereby indicating potential speciﬁcity to OA.
Prognostic biomarkers
Prognostic biomarkers seek to predict onset or progression of
disease. Using data from two phase III rheumatoid arthritis (RA) and
OA studies, Bay Jensen et al. measured serum CRP and CRPM26. While
both CRP and CRPM were signiﬁcantly higher in RA patients, levels in
OA patients were marginally higher, as compared to reference levels.
However, 20% of OA patients had CRP levels higher than 3 mg/L with
15% having CRP above 5 mg/L, thus suggesting that some OA patients
display a more pronounced inﬂammatory phenotype. In search for a
prognostic cut-off, 5% of the OA patients who had CRPM above 9 mg/
L and unilateral knee OA at study entry, had increased risk of
developing radiographic knee OA in the contralateral knee over 2
years. Moreover, though CRPM levels were associated with incident
contralateral knee OA, CRP levels were not. Apart from highlighting
“one model ﬁts all” is inadequate when prognosticating OA patients,
these data point to a need for larger, prospective, longitudinal
studies in order to determine whether CRPM levels can be used as a
prognostic biomarker in knee OA26.
Another recent study examined the association of serum levels
of type III collagen degradation (C3M), CRPM, and COMP with OA
symptoms and imaging changes in knee OA. There was a
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statistically signiﬁcant negative association of serum C3M and
CRPM with knee pain and function whereas synovitis and meniscal
changes were positively associated with knee symptoms. In addition to ﬁnding weak associations, the study design was crosssectional, without an adequate number of patients to adjust for
confounders27. Using data from the Osteoarthritis Initiative (OAI)
cohort, levels of inter-alpha trypsin inhibitor heavy chain 1 (ITIH1),
complement C3 (C3), and calcyclin (S100A6) were shown to be
positively associated with incident radiographic knee OA with high
predictive capacity (AUC ¼ 0.82). ITIH1 levels, combined with the
clinical model, increased the predictability of incident knee OA.
Although promising, particularly given the clinical feasibility, these
results need to be replicated in larger cohorts with adjustments for
confounders, including comorbidities and risk factors28.
Non-coding RNAs
MicroRNAs and lncRNAs have recently been explored for their
ability to predict both radiographic and symptomatic OA outcomes.
Leveraging the unparalleled proﬁling power of sequencing11, both
Ramos et al.29 and Ali et al.30 identify plasma microRNAs associated
with radiographic progression of OA. These studies utilized established OA cohorts including the Research Arthritis and Articular
Cartilage (RAAK) study and the Genetics osteoARthritis and Progression (GARP) study29, and the OAI cohort30, respectively. Ramos et al.
report 7 microRNAs (miR-1307-5p, miR-140-3p, miR-181a-3p, miR221-5p, miR-4326, miR-4443, and miR-99a-5p) to have AUC values of
0.86 over 2 years and 0.76 over 5 years in distinguishing progressors
from non-progressors29. Ali et al. report models with AUC values of up
to 0.92 when using the top predictive microRNAs (including members
of the miR-320 family: miR-320b/c/d/e) to discern fast-progressors
from both slow- and non-progressors over 8 years30. The lack of
overlap in putative prognostic microRNAs in these two studies could
be explained by differences in deﬁning the progression phenotype
(e.g., knee and hip29 vs knee30), including the follow-up time frame
examined. However, the strong AUC values show promise and suggest
validation in independent cohorts is merited.
Another study on circulating non-coding RNAs analyzed 84
lncRNAs in serum from knee OA patients and assessed pain intensity before and 1 year after total knee arthroplasty31. Giordano
et al. report 3 lncRNAs, namely Myeloid Zinc Finger 1 Antisense RNA
1 (MZF1-AS1), Metastasis associated lung adenocarcinoma transcript 1 (MALAT1), and Patched 1 pseudogene (LOC100287846), to
be downregulated pre-operatively among patients with chronic
post-operative pain vs those with normal post-operative pain31.
These data suggest circulating lncRNAs may be useful markers for
predicting pain outcomes following surgery, but also may be
contributing to molecular mechanisms underlying pain since 2 of
the 3 lncRNAs are known to be involved in neuropathic pain31.
Given the small sample size in this study (N ¼ 10 per group), independent validation is required.
Intervention
Viscosupplementation has been explored as a valuable alternative
to treat OA patients. In a group of 200 knee OA patients treated with
intra-articular hyaluronic acid (HA) or loxoprofen for 5 weeks, urinary
levels of CTX-II (uCTX-II) were shown to be signiﬁcantly higher in the
HA group of patients32. Similar to the above-mentioned studies, the
low number of patients and the time of observation, among other
issues, precludes a more in-depth analysis of these results. Sprifermin,
the recombinant ﬁbroblast growth factor (FGF)-18, has been studied
to treat knee OA, with a cartilage anabolic treatment proﬁle33. PRO-C2
was measured as a marker of type II collagen formation in synovial
and serum samples of patients from the 2-year phase IIb FORWARD
study to evaluate intra-articular (IA) sprifermin over placebo. PRO-C2
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levels signiﬁcantly increased in the sprifermin group, and patients in
the placebo group with low PRO-C2 levels had more cartilage loss as
compared to those in this group with higher PRO-C2 levels33.
Although data are not conclusive regarding the usefulness of PRO-C2
as a biomarker for response to treatment, they suggest an anabolic
response following sprifermin use, which needs further validation.
Non-pharmacological treatments are a “must use” recommendation in OA. A study evaluated the beneﬁts of balneological
treatment (peloidotherapy þ hydrotherapy) in knee OA and the
possible association with changes in serum levels of IL-1b, TNF-a,
and insulin-like growth factor-1 (IGF-1). Sixty-four patients were
divided into two groups, either receiving balneotherapy or a control
therapy, and were evaluated up to 6 months after treatment. There
were neither clinically relevant differences in response to treatment nor between serum cytokine levels, potentially due to
methodological issues that impaired data comparison34. Physical
activity can inﬂuence levels of extracellular matrix and/or bone
degradation/neoformation products, as well as inﬂammatory mediators in biologic ﬂuids. At least two studies addressed this issue,
one with healthy young individuals and another with knee OA
patients, showing variation of collagen markers following exercise35,36. This should be taken into consideration as the level of
physical activity is typically not speciﬁcally addressed or measured
when conducting protocols aimed at associating soluble biomarkers with clinical parameters in OA patients. As such, physical
activity could represent a critical, yet underappreciated, confounding variable in biomarker studies.
Endotype
The possibility that different OA phenotypes combined with
molecular characteristics constitute particular endotypes has
gained much attention. The IMI-APPROACH cohort has gathered
data that allow discriminating different OA phenotypes using a
machine learning approach. Based on these data, three dominant
phenotypes associated with three endotypes were characterized, as
follows: C1) low tissue turnover (low repair and articular cartilage/
subchondral bone turnover), C2) structural damage (high bone
formation/resorption, cartilage degradation), and C3) systemic
inﬂammation (joint tissue degradation, inﬂammation, cartilage
degradation). Results were consistent when applied to the FNIH/
OAI cohort3. This paper was included in order to put forth a
recommendation that interventions in OA patients be designed
with phenotyping and endotyping parameters in mind.

to biomarkers following interventions, and emerging data reinforce
that physical activity might impact serum levels of inﬂammatory
mediators, thus indicating we should control for sedentary vs active
behavior when comparing treatment modalities35,36. Although still
in the early preclinical stage, qualitative changes, namely modiﬁcation of the charge of extracellular components of the cartilage, may
better serve as a biomarker rather than measuring increase or
decrease of cartilage and/or bone components6,7.
Notable themes pertaining to study limitations arose during our
evaluation of the literature included in this review. Looking at
endpoints, joint replacement status and outcomes are frequently
used as surrogates for OA severity but clinicians and surgeons, not
to mention patients, are well aware that many patients either do
not want or are not eligible for surgery, which can bias evaluation.
Across studies, small sample size and discrepancies in phenotype
deﬁnition contribute to the lack of reproducibility, thereby limiting
clinical translation. Going forward, well-powered studies with
precisely deﬁned cohorts are required. Additionally, there is opportunity to explore composite biomarkers, particularly with
respect to non-coding RNAs and their downstream gene targets
which may have functional roles in OA pathology.
We conclude our narrative review with an article on endotypes
with the goal of emphasizing that the “one size ﬁts all” strategy is
counterproductive in the care of OA patients. Moving forward, we
anticipate seeing more studies that separate clusters of phenotypes
and endotypes in this disease. Although this year produced the
largest biomarker study in OA to date5, there remains a need for
multi-center studies with appropriate longitudinal design and inclusion of diverse patients in order to advance this ﬁeld. As of now,
because validation studies are still needed, precisely which
biomarker candidates are most promising remains subject to individual interpretation. We anticipate continued effort in OA
biomarker research will bring us closer to the day a useful tool will
reach the clinical arena.
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Discussion
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Identifying reliable biomarkers for OA has been a challenge for
some years despite concerted effort from the research community.
As outlined above, making an OA diagnosis typically does not
present a major issue1. On the other hand, although radiographies
are widely used to assess disease severity, imaging parameters lack
a direct correlation with joint pain and function, which represent
the most pressing issues for the individual OA patient1. Thus, having biomarker(s) to assess disease burden in terms of symptoms,
function, and progression, as well as changes secondary to intervention is a major unmet need in OA management.
This last year brought data on a promising biomarker to be used in
the clinical scenario, namely CRTAC1 plasma levels5. Levels of this
protein were associated with OA diagnosis in various joints as well as
with disease severity. Data on non-coding RNAs may also be useful in
clinical research as a tool for discriminating patients according to OA
status or progression. There is perhaps reduced enthusiasm for lipid
compounds given the data showing a lack of association with OA
parameters. There remains a need for studies evaluating alterations
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